Gennev LegitScript and Accreditation Status: Is Gennev Legit?

What Is Gennev and Who Owns It?

Gennev launched in 2016 as a direct-to-consumer menopause telehealth service. In January 2022, Unified Women's Healthcare, one of the largest women's health physician groups in the United States, acquired Gennev. That acquisition changed the operational structure meaningfully: Gennev's clinical operations became integrated with a network of OB/GYN practices rather than remaining a standalone digital startup.

The platform offers synchronous video visits with licensed clinicians, asynchronous messaging, health coaching, and prescriptions for hormone therapy including FDA-approved estradiol patches, gels, and oral micronized progesterone. It also offers non-hormonal options such as low-dose paroxetine (Brisdelle), the only FDA-approved non-hormonal treatment for moderate-to-severe vasomotor symptoms as of this writing. [1]

Clinical Model

Gennev's clinical model pairs patients with OB/GYNs or nurse practitioners who have menopause-specific training. Some providers list membership in the North American Menopause Society (NAMS), the professional body that offers the Menopause Practitioner Certified (MSCP) credential. The NAMS 2023 position statement on hormone therapy states: "Hormone therapy remains the most effective treatment for vasomotor symptoms and is approved for the prevention of osteoporosis." [2] Clinicians aligned with that standard are generally better positioned to provide evidence-based menopause care than generalists without subspecialty exposure.

Ownership and Corporate Structure

The Unified Women's Healthcare acquisition matters for accreditation questions because large physician group networks often carry facility-level credentialing that standalone telehealth startups lack. Patients researching Gennev's legitimacy should look at the parent organization's credentials, not only the consumer-facing brand.

LegitScript Certification: What It Is and Whether Gennev Has It

LegitScript is a Portland-based compliance company that certifies online pharmacies, telehealth platforms, and addiction treatment providers. Its telehealth certification program, launched in 2019, evaluates whether a platform employs licensed clinicians, prescribes only FDA-approved medications, complies with the Ryan Haight Act, and maintains transparent business practices. Google, Bing, and Meta require LegitScript certification before allowing telehealth advertisers to run paid healthcare ads in most categories.

What the Certification Actually Checks

LegitScript's telehealth program examines five core areas:

• State licensing of clinicians and the telehealth entity
• Prescribing practices (no prescribing without a valid patient-provider relationship)
• Dispensing only through licensed pharmacies
• Transparent fee and refund disclosures
• No prohibited drug advertising (e.g., Schedule II controlled substances without a prior in-person exam under the Ryan Haight Act)

A LegitScript certification does not mean a platform is clinically excellent. It means the platform meets a baseline compliance threshold. Conversely, the absence of certification does not necessarily mean a platform is operating illegally; it may simply mean the company has not applied or has not yet been reviewed.

Gennev's Current LegitScript Status

A search of LegitScript's public directory at legitscript.com as of July 2025 does not return a verified certification for Gennev. This is notable because many competing menopause telehealth platforms, including some that prescribe compounded hormones, have pursued and obtained LegitScript telehealth certification as a trust signal.

HealthRX's independent verification framework for telehealth legitimacy assigns LegitScript certification as one of five primary trust indicators. The others are: (1) state licensing transparency, (2) FDA-approved-only prescribing or compliant compounding pharmacy partnerships, (3) a clean or low-complaint BBB record, and (4) published clinician credentials. Gennev scores clearly on indicators 1, 2, and 4, but its status on LegitScript certification (indicator 3 in the compliance sense) and BBB complaint volume (indicator 5) is less definitive without a current direct verification.

Patients who want real-time confirmation should query LegitScript's search tool directly and contact Gennev's support team to ask whether the company holds or has applied for telehealth certification.

State Licensing and Ryan Haight Act Compliance

Under federal law, the Ryan Haight Online Pharmacy Consumer Protection Act of 2008 generally requires that a practitioner conduct at least one in-person medical evaluation before prescribing a controlled substance via the internet. Hormone therapy drugs, such as estradiol and progesterone, are not controlled substances, so Gennev's core prescribing activity does not trigger Ryan Haight restrictions. [3]

State-Level Telehealth Laws

Telehealth prescribing of non-controlled substances is primarily regulated at the state level. Each state sets its own rules about whether a clinician licensed in State A can treat a patient in State B (the "practice of medicine across state lines" issue). Gennev is available in most U.S. States, which implies it either employs clinicians licensed in each state or operates through Unified Women's Healthcare's multi-state credentialing infrastructure.

The Federation of State Medical Boards' Model Policy for the Appropriate Use of Telemedicine Technologies requires that a valid patient-provider relationship be established before prescribing. Gennev's intake process, which includes a synchronous video visit, satisfies that standard in most states. [4]

Pharmacy Partners

Gennev does not appear to operate its own pharmacy. Prescriptions route to major retail pharmacies (CVS, Walgreens) or mail-order partners. FDA-approved estradiol products are dispensed by state-licensed pharmacies, which is the preferred path for standard HRT. If a clinician prescribes compounded bioidentical hormones (cBHT) through a 503A compounding pharmacy, that pharmacy must be state-licensed and comply with USP standards, though cBHT itself is not FDA-approved. The FDA has stated clearly: "Compounded drugs are not FDA-approved." [5] Patients receiving compounded prescriptions from any telehealth platform, including Gennev, should ask which compounding pharmacy is used and whether it holds PCAB accreditation.

BBB Profile, Consumer Complaints, and Independent Reviews

The Better Business Bureau is not a government body and BBB accreditation does not equal clinical safety. Still, complaint volume and complaint-response patterns offer a signal about a company's customer-service practices and billing transparency.

What the BBB Record Shows

Gennev holds a BBB profile. Complaint categories that appear in consumer reviews across multiple third-party platforms (BBB, Trustpilot, Reddit) cluster around three themes:

1. Billing and insurance confusion: Patients report unexpected charges after being told a visit would be covered by insurance.
2. Prescription delays: Some patients report delays in receiving prescriptions after completing a visit, which is a meaningful problem when a patient is managing hot flashes or sleep disruption.
3. Coaching vs. Clinical care boundary: Several reviewers note frustration that health coaches cannot adjust prescriptions and that reaching a prescribing clinician requires a separate paid visit.

These complaint types are not unique to Gennev. They appear in consumer reviews of nearly every telehealth menopause platform. The pattern does not indicate fraud; it indicates the operational friction that comes with insurance-integrated telehealth at scale.

Positive Review Themes

Counterbalancing complaints, verified positive reviews consistently cite:

• Clinician knowledge of menopause-specific research, including the WHI reanalysis and NAMS guidelines
• Access to FDA-approved HRT without the dismissiveness some patients report from in-person generalists
• The convenience of asynchronous messaging for follow-up questions

Clinical Evidence Behind Gennev's Core Treatments

Gennev's legitimacy as a clinical platform is inseparable from the evidence base for the treatments it prescribes. Two categories dominate its prescribing profile: systemic hormone therapy for vasomotor symptoms, and low-dose vaginal estrogen for genitourinary syndrome of menopause (GSM).

Systemic Hormone Therapy

The Women's Health Initiative (WHI) initially (2002) raised alarm about estrogen-progestin therapy and breast cancer risk. Subsequent reanalysis has substantially refined that picture. The Menopause Society 2023 position statement concludes that for women under 60 or within 10 years of menopause onset, the benefits of hormone therapy generally outweigh the risks for treating vasomotor symptoms. [2] Transdermal estradiol, which Gennev clinicians prescribe, may carry lower VTE risk than oral conjugated equine estrogens, based on observational data from the E3N cohort study (N=80,377), which found a non-significant odds ratio for VTE with transdermal estradiol alone compared to an OR of 4.2 (95% CI 1.5-11.6) for oral estradiol plus progestogen. [6]

Vaginal Estrogen and GSM

Low-dose vaginal estrogen (estradiol cream, Vagifem tablets, or Imvexxy inserts) produces minimal systemic absorption. The 2020 ACOG Practice Bulletin on GSM states that low-dose vaginal estrogen is safe even in most breast cancer survivors when non-hormonal therapies have failed, though oncologist coordination is recommended. [7] Gennev's ability to prescribe these agents via telehealth is clinically appropriate when a proper intake history has been taken.

Non-Hormonal Options

For patients who cannot or will not use estrogen, Gennev can prescribe paroxetine mesylate 7.5 mg (Brisdelle), the only FDA-approved non-hormonal vasomotor symptom treatment as of 2025. [1] Fezolinetant (Veozah), a neurokinin 3 receptor antagonist approved by the FDA in May 2023 for moderate-to-severe vasomotor symptoms, is another non-hormonal option that evidence-based menopause clinicians may prescribe. The key SKYLIGHT 1 trial (N=501) showed fezolinetant 45 mg reduced mean daily hot flash frequency by 60% vs. 34% for placebo at week 12. [8]

How Gennev Compares on Accreditation Metrics

Comparing Gennev against the accreditation field helps contextualize its standing.

URAC and NCQA Telehealth Accreditation

URAC and the National Committee for Quality Assurance (NCQA) both offer telehealth organization accreditation programs. These are distinct from LegitScript (which focuses on compliance) and address clinical quality management, utilization review, and patient safety processes. No publicly available documentation confirms Gennev or Unified Women's Healthcare holds URAC telehealth accreditation, though Unified Women's Healthcare as a large physician group likely participates in payer credentialing processes that require similar quality documentation.

NAMS Certification of Individual Clinicians

NAMS offers the Menopause Practitioner Certified (MSCP) designation to clinicians who pass a competency examination. The NAMS website allows public verification of MSCP holders. Patients using Gennev can and should ask their assigned clinician whether they hold the MSCP credential and verify that claim at menopause.org/find-a-provider. [2]

The NCQA Health Plan Accreditation Question

Because Gennev accepts some commercial insurance, claims processing flows through Unified Women's Healthcare's billing infrastructure. That infrastructure is subject to insurer credentialing requirements, which indirectly impose quality standards even in the absence of a Gennev-specific NCQA accreditation.

Red Flags to Watch For With Any Menopause Telehealth Platform

No single accreditation resolves every safety concern. Patients evaluating Gennev or any comparable service should watch for these specific warning signs:

Prescribing without a synchronous visit or detailed asynchronous intake: The FSMB model policy and most state medical boards require a valid patient-provider relationship before prescribing. A platform that issues a prescription after only a symptom quiz has not met that standard. [4]

Compounded hormone prescriptions without disclosure of the compounding pharmacy's license: The FDA's BeSafeRx campaign specifically warns consumers to verify that any online pharmacy dispensing their medication is licensed in their state. [5] Ask for the pharmacy's NABP e-Profile number.

Vague or absent pricing disclosures: FTC regulations require clear disclosure of subscription terms and cancellation policies. Gennev's membership model involves recurring billing; confirm the cancellation process before subscribing.

Clinicians without verifiable licenses: Every clinician's name and state license can be verified through the relevant state medical board website. Do this before your first visit.

What Patients With Complaints Should Do

If you have an unresolved complaint about Gennev, you have four formal channels:

1. Better Business Bureau: File at bbb.org. BBB complaint submission triggers a formal response requirement from the company.
2. State Medical Board: If your complaint involves clinical care (a clinician prescribed something inappropriate or failed to conduct an adequate intake), file with the state medical board where the clinician is licensed.
3. State Attorney General: Billing complaints involving deceptive practices can be filed with your state's consumer protection division.
4. FDA MedWatch: If you experienced an adverse event related to a drug prescribed through Gennev, report it at fda.gov/safety/medwatch. [5]

The FDA's MedWatch program collects adverse event data that informs post-market drug surveillance. A single report contributes to the national safety signal database.

Summary of the Evidence: Is Gennev Legit?

Gennev is not a fraudulent operation. It employs licensed clinicians, prescribes FDA-approved medications for an evidence-supported indication, operates within state telehealth laws, and is backed by a large, established women's health physician group. These are meaningful legitimacy markers.

The gaps are specific. LegitScript certification is absent from the public directory as of this review's publication date. BBB complaint patterns reveal real service-delivery friction around billing and prescription logistics. No published documentation confirms URAC, NCQA, or PCAB accreditation for Gennev's compounding pharmacy partnerships, if any exist.

For a patient seeking menopause care, Gennev is a reasonable option if the assigned clinician holds the MSCP credential, the prescribed medication is FDA-approved and dispensed by a licensed retail or mail-order pharmacy, and the billing terms have been confirmed in writing before the first charge.

Verify the clinician's MSCP status at menopause.org before your first appointment.